Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E — 602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence
For best results when printing this announcement, please click on link below: Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence — Presentation will provide interim Phase 2 clinical da